We proudly deliver best-in-class consulting services to our clients in the Life Sciences Industry. Our team is built based on high levels of industry expertise and a strong commitment to serving as a strategic partner to our clients. We believe teamwork and trust provide a foundation for optimal results. As Excellis continues to achieve success, we encourage our employees to take leadership initiative within the company.
Excellis Health Solutions offers a service to ensure the most up-to-date information pertaining to legislation and how it may affect your company through a yearly subscription.
Global Track and Trace (GTT) members can access GMIS country slide information through the link below.
With the deadline for the Falsified Medicines Directive (FMD) approaching, EMVO has issued guidance as it relates to the On-boarding process for manufacturers. This guidance advises all On-Boarding Partners and future On-Boarding Partners that the final opportunity to on-board into EMVO with a guarantee of making compliance deadlines is June 2018.
On January 16, 2018, the FDA released a guidance document, Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices. This guidance, with initial intent released in June 2017, describes FDA’s intention with regard to enforcement of these requirements for class I and unclassified devices.
On January 24, 2017, the Government of the Russian Federation and several government agencies announced and released a decree to implement a system for the identification and monitoring of all pharmaceutical products in the Russian market, known as the “Medicines Quality and Safety” project.
The FDA released the Grandfathering policy on November 27, 2017. Although this guidance is exactly two years late (Based on the DSCSA timeline), it provides clear direction on the grandfathering policy.